title: Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis.
abstract: BACKGROUND
  Recently, rimabotulinumtoxinB has been increasingly used as an off-label treatment of primary axillary hyperhidrosis (PAH). However, the optimal conversion ratios for onabotulinumtoxinA and rimabotulinumtoxinB remain to be determined.
  
  
  OBJECTIVE
  To compare effectiveness, satisfaction level, and safety of rimabotulinumtoxinB with onabotulinumtoxinA at a conversion ratio of 1:30 for the treatment of PAH.
  
  
  METHODS
  Adults with PAH were enrolled in this bilaterally paired single-subject study. Each patient was randomly treated with 1,500 U rimabotulinumtoxinB on 1 axilla and 50 U onabotulinumtoxinA contralaterally. Hyperhidrosis Disease Severity Scale was assessed before and after treatment up to 20 weeks. A 10-cm visual analog scale representing improvement of hidrotic symptom and starch-iodine test were also used to assess therapeutic efficacy.
  
  
  RESULTS
  Twenty-four patients completed the study. Both groups showed comparable and efficacious anhidrotic effects through 20 weeks for any variable. There were no significant differences in terms of the onset of action or mean duration of action between the 2 groups. Overall satisfaction with the treatment was equally high in both groups.
  
  
  CONCLUSIONS
  Both toxins showed comparable anhidrotic effect for the treatment of axillary hyperhidrosis at a conversion ratio of 1:30.
authors.affiliation: *Department of Dermatology, Modelo Clinic, Seoul, Korea; †Department of Dermatology, School of Medicine, Ulsan University, Seoul, Korea; ‡Department of Dermatology, Seoul National University Boramae Hospital, Seoul, Korea.
authors.forename: Jee Soo
authors.initials: JS
authors.lastname: An
authors.forename: Chong
authors.initials: C
authors.lastname: Hyun Won
authors.forename: Ji
authors.initials: J
authors.lastname: Si Han
authors.forename: Hyun Sun
authors.initials: HS
authors.lastname: Park
authors.forename: Kyle K
authors.initials: KK
authors.lastname: Seo
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001365:Axilla; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D064232:Visual Analog Scale; D055815:Young Adult
chemical_list: D065087:Acetylcholine Release Inhibitors; C096323:rimabotulinumtoxinB; D019274:Botulinum Toxins, Type A